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BioBAnKs: EuropEAn situAtion
Ethical issues in biobanking, as well as organization and 
management of biobanks, have become permanent topic 
of scientific publications in the last 15 years (1). The Expert 
Group of the European Commission Defines biobanks as 
collections of various types of biological samples (cells, tis-
sues, blood, DNA) plus related databases. They can be small 
collections or large national repositories, population-based 
or disease specific, established for diagnostic, therapeutic 
(eg, transplantation), forensic, or research purposes (1-3).
Different countries in Europe have different types of 
biobanks, and the material is collected in different ways for 
different purposes (2-7) (Table 1). For example, there are 
different approaches to obtain informed consent depend-
ing on the type and the use of the collected tissue samples 
and whether the material is irreversibly anonymized or not. 
In biobanks with irreversibly anonymized samples, no infor-
mation regarding the donor can ever be obtained from the 
sample. In these cases, no informed consent is obtained 
because the donor’s consent is presumed if he or she does 
not opt out. The same process is used in some European 
countries when leftover tissue is concerned (eg, Belgium, 
Denmark, and the Netherlands). The future donors receive 
the information about potential use of their leftover tissue 
and they are given the possibility to opt out.
When it comes to the procurement of tissue for diagnostic 
purposes that may later be used for research or in sam-
ple collections exclusively created for research purposes, 
informed consent can be obtained in the several ways. In 
tABLE 1. European biobanks
type of bio bank purpose of the material collection type of tissue collected and storage Countries
Population 
biobanks
population research mainly blood (frozen samples) Island, Estonia, Latvia, Hungary, 
Poland, United Kingdom
Biobanks oriented to 
specific diseases
research of specific disease different types of tissue (frozen 
samples)
majority of European countries
Biobanks created during 
the course of clinical trails
research purposes different types of tissue (frozen 
samples)
majority of European countries
Diagnostic 
archives
diagnosis of disease 
(mainly pathological archives)
different types of tissues (mainly paraf-




forensic (criminalistics) purposes 
(identification of victims or crime 
perpetrator)
blood, urine, semen, bone tissues and 
other tissues (frozen samples)
majority of European countries
Transplantation biobanks 
(eye banks, cord blood banks)
therapeutic purposes 
(organ transplantation)
different types of tissue (frozen 
samples)
majority of European countries
Biobanks of 
leftover materials
research different types of tissue (frozen 
samples)
some European countries eg, 
the Netherlands
Blood banks therapeutic purposes (transfusion) blood, frozen samples all European countries
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broad consent schemes, permission is given for the ma-
terial to be used for all future research purposes. Partially 
restricted consent allows the use of the material in cer-
tain types of research studies done in a certain scientific 
filed. Specific consent allows the use of the obtained ma-
terial only in one research project. Biobanks sometimes of-
fer tiered or multi-layered consent. This means that each 
donor can choose whether the sample can be used in all 
types of research, only in certain studies, or only in one 
specific research project (2,7,8).
On the theoretical level, no consensus seems to exist which 
consent model fits best as the consent model for balanc-
ing the interests of donors and research. Recently a new ap-
proach for biobanking has been proposed – dynamic con-
sent model. Dynamic consent uses modern communication 
strategies to inform, involve, offer choices, and obtain con-
sent for every research project based on biobank resources. 
Such approaches usually use web-based platforms with an 
interface that allows interactive communication of research 
participants with custodians of biobanks (9,10).
The work of biobanks is monitored by experts based on 
quality standards in the field and by ethic of governance 
or ethics and governance committees. This new type of 
ethics committee reviews proposals for different projects 
connected with a certain biobank, protects the future re-
search subjects, monitors and informs the public about 
the research and biobank functioning, approves date ex-
change and transfer, and revises guidelines and working 
frameworks regarding recruitment access or handling of 
complaints (5,11).
The legal basis for establishment of biobanks is left for each 
country to implement according to its own legal standards. 
Therefore the United Kingdom, Estonia, Sweden, Portugal, 
and Iceland have their own national legal standards that 
regulate the foundation and management of different 
biobanks (6,12). Other countries decided to draft national 
recommendations regarding biobanks (eg, Germany, Aus-
tria, Cyprus) (12,13). In addition, there are some common 
EU standards to be followed (13) (Table 2).
Since in 2011 an incentive for coordination of biobanks was 
proposed, several such projects have been launched (15), 
among which was Biobanking and Bimolecular Resources 
Research Infrastructure (BBMRI). The project recruited 270 
associated organizations, mostly biobanks linking 20 mil-
lion biological samples in 22 countries (14) (Table 3).
It is still not clear to what degree biobanks will be able to 
generate new knowledge that can be exploited and uti-
lized in the health care sector and for development of 
products and services. Therefore, some biobanks will be 
forced to close or be substantially reconfigured since the 
benefits of biobanking are sometimes very difficult to be 
operationalized in economic terms. There are reports of 
biobanking managers who struggle with problems hop-
ing their biobanks will exist permanently despite limited 
funding (16).
BioBAnKs: CroAtiAn situAtion
In Croatia there are several biobanking facilities intended 
for various purposes. In the 1980s Croatian Bone Marrow 
Donor Registry (CB-MDR) was established at the University 
Hospital Centre Zagreb, which performs sporadic HLA typ-
ing of family members in the cases of bone marrow trans-
plantation. The Cord Blood Bank (CBB) was established in 
the same period at the University Hospital Center Zagreb. 
tABLE 2. Common European union legal biobanking framework
Lisbon treaty
(title XIV devoted to public health Article (168) 4 promotes common safety standards of quality and safety when it comes to organs and 
substances of human origin, blood and blood derivatives)
Directive 2004/23/EC, 2006/17/EC
(standards on quality, safety, donation, procurement, testing, processing, preservation, storage and distribution of human tissues and 
cells used in donation and serious adverse events that may be in connection to it)
Directive 95/46/EC (data protection)
Additional protocol to the Convention on Human rights and Biomedicine concerning Biomedical research
Additional protocol to the Convention on Human rights and Biomedicine concerning Genetic testing for Heath purposes
opinion no 11 on Ethical aspects of human tissue biobanking from 1998 of the European Group on Ethics in science and new 
technologies
Council of Europe recommendations: recommendations no r(94)1 on human tissue banks
recommendation rec (2004) 4 of the Committee of Ministers to member states on research on biological materials of human origin,
recommendation no r(92)1 on the use of DnA (DnA) within the framework of criminal justice system
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In 2007, Foundation “Ana Rukavina” was set up as a result 
of a large campaign following the death of a young fe-
male journalist. Foundation “Ana Rukavina” nowadays in-
cludes an allogeneic public cord blood bank and a reg-
istry of potential allogeneic bone marrow donors. At the 
University Hospital Center Zagreb, there is also a private 
cord blood bank for autologous use. Clear quality control 
standards, protocols for international exchange of samples 
and procurement, and informed consent procedures are 
in place based on international and national legal frame-
works: EU Directives 2004/23/EZ, 2006/17/EZ, 2006/17/EZ, 
2010/453/E, and the Law on Procurement and Transplan-
tation of Human Body Parts for the Purpose of Therapeutic 
Procedures and its bylaws (17-19).
In Croatia, there is also a blood bank, which is a part of the 
Croatian Institute for Transfusion Medicine. The bank has 
regional organization structure and is based on general 
population’s voluntary donation of blood. The bank is well 
organized with high quality standards and legal provisions 
(laws and bylaws) in place: EU Directive 2005/61and Law 
on Blood and Blood derivates (20,21).
The first Croatian eye bank – Croatian Lions Eye Bank 
(LHOB) was founded at the Clinical Hospital “Sv. Duh” in Za-
greb in the 1980s. LHOB acts in accordance with the stan-
dards of the European Association for Ocular Banking. It 
provides tissues for corneal transplantation and process-
es and stores amniotic membranes and sclera used in the 
surgical treatment of diseases of the anterior eye segment. 
Several years later, an eye bank was also founded at the 
University Hospital Center Zagreb. Their work is covered 
by the Law on Procurement and Transplantation of Hu-
man Body Parts for the Purpose of Therapeutic Proce-
dures and its bylaws (22).
Diagnostic archives have been a permanent fixture of Cro-
atian health care system as part of pathology departments 
in different health care institutions. They are well organized 
and regulated by legal provisions based on Health Protec-
tion Act (23).
Banks of frozen embryos and sperm have been present in 
Croatia for many years since the first introduction of artifi-
cial insemination and IVF procedures. They have been the 
object of debate and controversy for several years because 
of the lack of legal provisions regulating their work. Now 
their work is clearly ruled by the Law on Medically Assisted 
Procreation and its bylaws (24).
Croatia has been involved in DNA identification of the vic-
tims from the 1991-95 war in Croatia and the region since 
the beginning of the war. The result of these efforts are two 
forensic DNA laboratories at the Schools of Medicine at the 
University of Zagreb and Osijek, and one laboratory at the 
University Hospital Split. Their work is mandated by the 
Geneva Conventions and Rules on Collection of Biological 
Samples for DNA Analysis (25,26). All these collections form 
a bio-bank of DNA samples for identification purposes. The 
owner of the bio-bank is the Ministry of War Veterans. The 
contract with those laboratories is renewed every year by 
the Ministry, which procures their services and facilities in 
order to continue with this work and use the biobank (26).
Together with these forensic laboratories, the forensic lab-
oratory at the Ministry of the Interior located at the Foren-
sic Science Centre “Ivan Vučetić” and at least one private 
laboratory are capable of doing forensic DNA analysis. 
Their work in this area is regulated by the Criminal Proce-
dure Act and Prison Sentence Act. In Croatia it is obliga-
tory to take biological samples and perform forensic DNA 
tABLE 3. European biobanking networks
project name project aim
TUBAFROST virtual tumor tissue bank of frozen tumor tissues
EROBIOBANK network of biobanks connected with the research of rare disease (human DNA, cell and tissue 
samples) – 15 members from France, Germany, Hungary, Italy, Malta, Slovenia, and Spain
CONTICANET connective tissue cancers biobanks network
BBMRI pan European and internationally broadly accessible network of existing and de novo created 
biobanks and bimolecular resources
CNIO Tumour Bank Network Spanish tumor hospital banks
Euro BoNeT project primary bone tumor bank
Confederation of Cancer Biobanks UK-based consortium for development, management and use of biobanking resources for 
cancer research
The NCI Office of Biorepositories 
and Biospecimen Research (OBBR)
established in 2005 for developing common bio-repository infrastructure
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analysis for criminal offenses with a minimum sentence of 
6 months. Data collected through DNA analysis have to be 
stored for 20 years (25,27-29). Currently a new bylaw is in 
process of adoption concerning the procurement of bio-
logical samples and the modes of forensic DNA analysis, 
which aims to set additional quality standards and facili-
tate the establishment of a forensic DNA biobank. Accord-
ing to this proposal, all the forensic evidence can only be 
kept at the Forensic Science Centre of the Ministry of the 
Interior. The following questions remain: What will become 
of the samples and data already collected and stored by fo-
rensic laboratories at Universities? Will they be destroyed? 
Will they be transferred? Will other laboratories be able to 
also do DNA analysis or only the Forensic Centre of the 
Ministry of the Interior? Can private laboratories perform 
forensic DNA analysis?
Croatia also has a population biobank – The 100 001 Dal-
matians Biobank. This is an isolated population biobank 
with a focus on genetic basis of complex diseases and a tar-
get sample of 100 001 individuals (30,31). Today it contains 
samples of about 4500 individuals from six Croatian islands 
(Vis, Korčula, Mljet, Lastovo, Rab, Susak) and the city of Split. 
Among other research biobanks at different research insti-
tutions and medical schools in Croatia, there is a mini-bank 
of testicular biopsies at the University of Zagreb School of 
Medicine (32,33). However, when it comes to population 
biobanks or different research biobanks there are no legal 
provisions regulating their work. Except for a private cord 
blood bank in Croatia there are also private DNA laborato-
ries involved in DNA diagnostics and research with small 
DNA collections. A set of standards should be given re-
garding their organization, management, quality control, 
and conditions for international exchange of samples and 
procurement and informed consent (29).
CroAtiAn nAtionAL CEntrE for BioBAnKinG
Some biobanking facilities in Croatia are already well or-
ganized and some are still in the developing phase. The 
majority of the authors of this paper have been involved in 
the biobanking organization or research. Drawing on their 
experiences they came up with a way to improve the cur-
rent Croatian biobanking situation by creating a national 
network of different Croatian biobanks – Croatian National 
Centre for Biobanking (Figure 1).
fiGurE 1. the Croatian national Center for Biobanking – organizational structure.
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The Croatian National Centre for Biobanking would be a 
virtual network of all biobanks in Croatia coordinated by 
the representatives of different Croatian biobanks. The re-
positories would be left at the same places but the qual-
ity of their work would be monitored centrally. We be-
lieve that such approach would not require substantial 
financial resources because the already existing resourc-
es would be put under one roof preventing redundan-
cy and improving the coordination between different 
biobanking facilities. The management structure would 
consist of a scientific advisory committee and an ethics 
governance committee, ie, the expertise already existing 
in different biobanks.
The Scientific Advisory Committee would consist of one 
member from each of the biobanks present in the consor-
tium and four external experts coming from the field of 
biobanking in Croatia or outside of Croatia. Its main task 
would be to monitor the implementation and execution of 
quality control standards in procurement, storage, sample 
shipment, and scientific work done within the consortium 
of biobanks.
The Ethics Governance Committee would be in charge 
of implementing and monitoring the procedures of ob-
taining informed consent and dealing with other ethical 
challenges, such as the protection of vulnerable subjects, 
safeguarding of privacy, communication of research re-
sults to donors, conflicts over patenting, access, and the 
need for open science, the rights of donors to retain a 
property claim or control over their tissues, and the man-
agement of samples collected from vulnerable groups. 
Furthermore, one of the tasks of the Ethics Governance 
Committee would also be the provision of the transpar-
ent information about the work and research done within 
the biobanking consortium to the general public. Finally, 
it would be involved in a campaign of ethical education to 
ensure that all researchers involved in biobanks are aware 
of their ethical responsibilities, and that donors are better 
informed of ethical aspects of donation. The committee 
would consist of five independent experts coming from 
the fields of ethics, law, and biobanking and two members 
of general public.
The two committees would meet at least twice year at the 
premises of one of the consortium members to discuss 
the current work and problems within the consortium. 
They would annually submit their reports to the Minis-
try of Health, Ministry of Science, Education and Sport, 
Ministry of War Veterans, and the Ministry of the In-
terior, since the biobanks in the consortium are related to 
their respective areas of work.
Croatian National Centre for Biobanking requires improved 
legal provisions, especially for research biobanks, popula-
tion biobanks, and private DNA laboratories in particular. 
The informed consent procedures needed for sample pro-
curement should be clearly set, with the tiered or multi-lay-
ered model as the best choice. Donors should be allowed 
to decide whether they want to donate their samples for 
research purposes and if the sample would be used for all 
types of research, only for certain studies, or only for this 
specific research study. The previously collected material 
for diagnostic purposes could be used for research only 
with the approval of a research ethics committee and if it 
is irreversibly anonymized. The material previously collect-
ed for other biobanks could only be used for the research 
specified in previously collected informed consent proce-
dures. In the future also the possibility of introduction of 
dynamic consent practices could be discussed. However, 
special attention should be paid to avoiding therapeutic 
misconceptions (9).
The work of the network should be coordinated with the 
Ministry of Health, Ministry of Science, Education and 
Sport, Ministry of War Veterans, and Ministry of the Interior 
since the biobanks in the consortium are related to their 
respective areas of work.
Our model of the Croatian National Centre for Biobanking 
is based on the model proposed for the Polish national 
DNA bank by Sak et al (6). Sak’s model is a model for a 
possible population biobank, but we have a different aim 
– brining all biobanking facilities together and improving 
the existing legal standards for biobanking in Croatia. We 
feel that our approach can be useful for small countries 
like Croatia. Why?
In the past Croatia was faced with similar challenges when 
it came to clinical trials. Before 2003, all clinical trials were 
reviewed locally by different research ethics committees 
in different hospitals. After 2003, new legal standards were 
created regulating this field and the review process of clini-
cal trials was centralized at the Croatian Agency for Drugs 
and Medical Devices. This led to greater transparency of 
the review process, avoiding possible conflicts of interests. 
It created no waste of expertise and resources and allowed 
a better public control of the process (34). We, therefore, 
feel that the same benefit can be found in the networking 
of all biobanking facilities in Croatia.
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Moreover, it seems that when it comes to biobanking 
practice in smaller countries like Slovenia or Cyprus there 
is a tendency to have a centralized national approach. This 
can bring together all the existing biobanking expertise 
and create better coordination and bigger research po-
tential (35,36).
The Croatian National Centre for Biobanking with its pro-
posed structure would be able to promote transparency 
and public interest in biobanking in Croatia, which in turn 
would enable biobanks to get more samples. It would safe-
guard ethical and quality standards in biobanking through 
harmonization and the ethical governance of the existing 
biobanking facilities. It would also prevent conflicts of in-
terest that may arise in everyday work of biobanks. Finally, it 
would bring together all the existing resources to enhance 
research quality and facilitate exchange of samples and 
information under well regulated and transparent condi-
tions within Croatia and with other countries.
In Europe new biobanks have been set up that will be-
come part of international networks for exchange and re-
search. National systems for collection and exchange of 
tissue samples and related material have also been devel-
oped around the world. It is not clear whether these na-
tional biobanking initiatives overlap or reproduce efforts 
which are being under way in other countries or even in 
their own country. When it comes to national biobanking 
schemes, the issues of sustainability and excessive finan-
cial costs are also being raised (16). We hope that with the 
Croatian National Centre for Biobanking we would be able 
to avoid these pitfalls.
We also hope that scientific community in Croatia will put 
forward their expert opinion about our proposal and that 
our ideas will lead to further discussions and actions on the 
part of all involved in the field of biobanking in Croatia as 
well as the Croatian government.
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